Verticillin A, Therapeutic Agent for Colon Cancer and Leukemia

Case ID:

2013-015*-a

Web Published:

7/13/2015

Description:

Title

Verticillin A, Therapeutic Agent for Colon Cancer and Leukemia

Current State of the Art

Histone specific methyltransferases (HMTase) are over expressed in certain colon cancer and leukemia cells. Inhibitors of HMTase prevent methylations of histone residues and inhibit the development and progression of the cancer cells.

Problem with the Current Art

Existing HMTase inhibitors when used as chemotherapeutic agents often lack applicability against the multi drug resistance of the cancer cells.

Advantage of Invention

Verticillin A, a naturally occurring cytotoxic compound that selectively inhibits certain HMTase and activates the binding of Fas proteins to the receptors. The Fas activation leads to the successful apoptosis of the cancer cells and the suppressing of the gene silencing effect. Vericillin A can be used as a potent therapeutic or combination therapeutic agent to treat and to prevent the multi-drug resistance of the cancer cells.